Skip to content
DataLookout
Menu

LIORANCT07947953

A Prospective, Randomized, Placebo-Controlled Double Blind, 18 Month Study Evaluating the Efficacy and Tolerability of Lithium Orotate 10 mg Daily in Patients With Alzheimer's Disease and Mild Cognitive Impairment.

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

2 Point change in MMSE Scores. Clock Drawing Tests change pass to fail or vice versa.
Timeframe: 18 months

Secondary (1)

Amyloid changes on PET Scans with Centiloid Scores.

Arms and interventions

Placebo

Placebo

Lithium Orotate 10 mg

Lithium Orotate will be given to half the participants to see if it prevents or reverses cognitive decline in MCI or Alzheimer's patients.

Sites

1 site in 1 country

  • Robert B Koser MdBradenton, Florida, United States